XyloCor Therapeutics Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
2ndary - Private
- Investors
-
6
XyloCor Therapeutics General Information
Description
Operator of a bio-pharmaceutical firm intended to develop gene therapy for people with advanced coronary artery disease. The company's firm focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patients with refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost-effectively.
Contact Information
Website
www.xylocor.comCorporate Office
- 1200 Liberty Ridge Drive
- Suite 120
- PA 19087
- United States
Corporate Office
- 1200 Liberty Ridge Drive
- Suite 120
- PA 19087
- United States
XyloCor Therapeutics Timeline
XyloCor Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 6. Later Stage VC (Series B) | 07-Jan-2025 | Completed | Clinical Trials - Phase 2 | |||
| 5. Grant | 01-Jan-2023 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series A1) | 14-Dec-2022 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series A1) | 20-Jan-2021 | Completed | Clinical Trials - Phase 2 | |||
| 2. Later Stage VC (Series A) | 21-Aug-2020 | $2.47M | $19.9M | Completed | Clinical Trials - Phase 1 | |
| 1. Later Stage VC (Series A) | 04-Oct-2018 | $17.4M | $17.4M | Completed | Clinical Trials - Phase 1 |
XyloCor Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-1 | ||||||||
| Series A | 10,532,398 | $0.001000 | $0.08 | $1 | $1 | 1x | $1 | 12.64% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
XyloCor Therapeutics Comparisons
Industry
Financing
Details
XyloCor Therapeutics Competitors (41)
One of XyloCor Therapeutics’s 41 competitors is Angionetics, a Corporate Backed or Acquired company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Angionetics | Corporate Backed or Acquired | San Diego, CA | ||||
| Imbria Pharmaceuticals | Venture Capital-Backed | Boston, MA | ||||
| Unity Biotechnology | Formerly VC-backed | South San Francisco, CA | ||||
| Apeptico | Venture Capital-Backed | Vienna, Austria | ||||
| Azitra | Formerly VC-backed | Branford, CT |
XyloCor Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
XyloCor Therapeutics Patents
XyloCor Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3153845-A1 | Epicardial delivery of gene therapy | Pending | 09-Oct-2019 | ||
| EP-4041192-A1 | Epicardial delivery of gene therapy | Pending | 09-Oct-2019 | ||
| EP-4041192-A4 | Epicardial delivery of gene therapy | Pending | 09-Oct-2019 | ||
| US-20240115732-A1 | Epicardial delivery of gene therapy | Pending | 09-Oct-2019 | A61K48/005 |
XyloCor Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
XyloCor Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Jeito | Growth/Expansion | Minority | ||
| U.S. Department of Health and Human Services | Government | |||
| Fountain Healthcare Partners | Venture Capital | Minority | ||
| Longwood Fund | Venture Capital | Minority | ||
| Lumira Ventures | Venture Capital | Minority |
XyloCor Therapeutics FAQs
-
When was XyloCor Therapeutics founded?
XyloCor Therapeutics was founded in 2013.
-
Where is XyloCor Therapeutics headquartered?
XyloCor Therapeutics is headquartered in PA.
-
What is the size of XyloCor Therapeutics?
XyloCor Therapeutics has 14 total employees.
-
What industry is XyloCor Therapeutics in?
XyloCor Therapeutics’s primary industry is Drug Discovery.
-
Is XyloCor Therapeutics a private or public company?
XyloCor Therapeutics is a Private company.
-
What is XyloCor Therapeutics’s current revenue?
The current revenue for XyloCor Therapeutics is .
-
How much funding has XyloCor Therapeutics raised over time?
XyloCor Therapeutics has raised $122M.
-
Who are XyloCor Therapeutics’s investors?
Jeito, U.S. Department of Health and Human Services, Fountain Healthcare Partners, Longwood Fund, and Lumira Ventures are 5 of 6 investors who have invested in XyloCor Therapeutics.
-
Who are XyloCor Therapeutics’s competitors?
Angionetics, Imbria Pharmaceuticals, Unity Biotechnology, Apeptico, and Azitra are some of the 41 competitors of XyloCor Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
